Clinical Trials on Leukemia, Myelogenous, Acute in China

Total 2012 results

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia

Acute Myelogenous Leukemia

China
Maxinovel Pty., Ltd.

Recruiting

Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

AML

China
Shenzhen People's Hospital

Unknown

Medium Dose of Cytarabine and Mitoxantrone (HAM)

Chemotherapy | Acute Myelogenous Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation

Patients With Recurrent Acute Myelogenous Leukemia After Transplantation

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia

Chronic Myelomonocytic Leukemia | Acute Myelogenous Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Acute Myeloid Leukemia | Acute Myelogenous Leukemia | Acute Myeloid Leukemia With Maturation | Acute Myeloid Leukemia Without Maturation | ANLL

China
Zhujiang Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Shenzhen Geno-Immune...

Recruiting

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

Myelodysplastic Syndromes | Leukemia, Acute Myelogenous (AML) | Leukemia, Acute Lymphocytic (ALL)

China
GeneScience Pharmaceuticals Co., Ltd.
Ruijin Hospital; Shanghai Tong Ren Hospital; First Affiliated Hospital of Zhejiang...

Recruiting

Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients

Chronic Myelogenous Leukemia

China
xuna

Recruiting

A Study for PRO of CML in Real Word (Case-Only)

CML (Chronic Myelogenous Leukemia)

China
Shenzhen TargetRx, Inc.
Peking University People's Hospital

Recruiting

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

Chronic Myelogenous Leukemia

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Dasatinib Tablet

Leukemia, Myelogenous, Chronic

China
Beijing GoBroad Hospital

Not yet recruiting

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Refractory/Relapsed Acute Myeloid Leukaemia

China
The First Affiliated Hospital of Soochow University

Completed

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Philadelphia Chromosome | Mixed Phenotype Acute Leukemia

China
First Affiliated Hospital of Zhejiang University
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Recruiting

Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Myeloid Malignancy | Relapsed/Refractory Acute Myeloid Leukaemia

China
Junmin Li

Suspended

Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+

Chronic Myelogenous Leukemia

China
Zhongnan Hospital
Shanxi Province Cancer Hospital; Ruijin Hospital; The First Affiliated Hospital... and other collaborators

Recruiting

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukaemia

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.; Union Stem cell & gene engineering Co.LTD

Completed

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult B-Cell | Acute Lymphoblastic Leukaemia Recurrent

China
Bristol-Myers Squibb

Completed

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Chronic Myelogenous Leukemia - Chronic Phase

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Myelogenous Leukemia, Chronic

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Myeloid Malignancy | Relapsed/Refractory Acute Myeloid Leukaemia

China
Nanfang Hospital of Southern Medical University
Xiangya Hospital of Central South University; Tongji Hospital; Guangzhou First... and other collaborators

Completed

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Chronic Myeloid Leukemia | Acute Leukemia | Myelodysplastic Syndrome

China
Pfizer

Completed

Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Chronic Myelogenous

Japan
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias

Chronic Myelogenous Leukemia

Japan
Novartis Pharmaceuticals

Completed

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib (LASOR)

Chronic Myelogenous Leukemia

China, Argentina, Russian Federation, Germany, Guatemala, Panama, Colombia, Mexico, Brazil, India, Poland, Venezuela
Peking University People's Hospital
Beijing JD Biotech Co. LTD.

Recruiting

Off-the-shelf CD123 CAR-NK for R/R AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Leukemia

China
Shenzhen Second People's Hospital

Recruiting

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Newly Diagnosed Acute Myeloid Leukemia (AML)

China
South China Children's Leukemia Group

Completed

A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia

Childhood Acute Promyelocytic Leukemia

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Takeda
Takeda Development Center Americas, Inc.

Active, not recruiting

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)

Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Myelodysplastic Syndrome

Australia, United States, Canada, Spain, Belgium, France, Czechia, Italy, Korea, Republic of, Israel, Brazil, China, Germany, Turkey, Japan, Greece, Poland, United Kingdom, Russian Federation, Mexico
The First Affiliated Hospital of Soochow University
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Newly Diagnosed | Acute Monocytic Leukemia

China
Xuzhou Medical University

Recruiting

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Xuzhou Medical University

Recruiting

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Affiliated Hospital to Academy of Military Medical...
Beijing JD Biotech Co. LTD.

Recruiting

Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia Refractory | Acute Myeloid Leukemia Recurrent

China
Xiaofan Zhu

Completed

Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL) (Ara-C)

Leukemia

China
Shanghai Jiao Tong University School of Medicine
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Unknown

Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL

Acute Promyelocytic Leukemia

China
Beijing Boren Hospital

Recruiting

Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse Leukemia

China
Institute of Hematology & Blood Diseases Hospital
Bejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...

Recruiting

Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Refractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, Childhood

China
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Acute Myeloid Leukemia, Adult

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.

Refractory Acute Myeloid Leukemia

China
Sunshine Lake Pharma Co., Ltd.

Terminated

A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

China
Institute of Hematology & Blood Diseases Hospital

Completed

Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia

Acute Myeloid Leukemia, Pediatric

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)

Leukemia, Myeloid, Acute

China
guomei

Recruiting

Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML

Adult Acute Myeloid Leukemia

China
Daiichi Sankyo Co., Ltd.

Completed

Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

China
iCell Gene Therapeutics
The General Hospital of Western Theater Command; Peking University Shenzhen... and other collaborators

Recruiting

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Novartis Pharmaceuticals

Completed

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Leukemia

China

Clinical Trials on Leukemia, Myelogenous, Acute in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations